Search Result

Results for "

Aβ42,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Amyloid-β (35) Apoptosis (6) ATM/ATR (1) Autophagy (1) Beta-secretase (1) Cathepsin (1) Cholinesterase (ChE) (4) COMT (3) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (1) Formyl Peptide Receptor (FPR) (2) HIV (1) Isotope-Labeled Compounds (2) NOD-like Receptor (NLR) (1) Notch (3) Organoid (1) Phosphatase (1) Ras (1) Somatostatin Receptor (1) Tau Protein (1) γ-secretase (23)
By Research Areas:	Cancer (8) Infection (1) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (59)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136866

Aβ42-IN-2	γ-secretase	Neurological Disease
Aβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC₅₀ of 6.5 nM for Αβ₄₂. Aβ42-IN-2 can be used for the research of Alzheimer's disease .

HY-149763

Aβ42 agonist-1	Amyloid-β	Neurological Disease
Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-149764

Aβ42 agonist-2	Amyloid-β	Neurological Disease
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-130609A

Aβ42-IN-1 free base	γ-secretase	Neurological Disease
Aβ42-IN-1 free base (compound 1v) is an orally active, high brain exposure γ-secretase modulator. Aβ42-IN-1 free base potently reduces Aβ42 levels with an IC₅₀ value of 0.091 µM, and significantly reduces brain Aβ42 levels in mice. Aβ42-IN-1 free base is a promising compound for the treatment of Alzheimer’s disease .

HY-130609

Aβ42-IN-1	γ-secretase	Neurological Disease
Aβ42-IN-1, compound 1v, is a novel, potent and orally active γ-secretase modulator (GSM). Aβ42-IN-1 potently reduced Aβ42 levels with an IC₅₀ value of 0.091 µM without CYP3A4 inhibition. Aβ42-IN-1 shows a sustained pharmacokinetic profile.

HY-161109

Aβ42-IN-4

Amyloid-β Neurological Disease

Aβ42-IN-4 (compound 0043) degrades amyloid precursor protein (APP) and reduces Aβ42 production .

Aβ42-IN-4	Amyloid-β	Neurological Disease
Aβ42-IN-4 (compound 0043) degrades amyloid precursor protein (APP) and reduces Aβ42 production .

HY-161110

Aβ42-IN-5	Amyloid-β	Neurological Disease
Aβ42-IN-5 (Compound 0152) is an oral active amyloid precursor protein (APP) degrader that can reduce Aβ42 in Alzheimer's disease iPSC neurons. Aβ42-IN-5 can bind CAPRIN1 and APP and enhance the protein-protein interaction .

HY-111267

Aftin-4

Amyloid-β Neurological Disease

Aftin-4 is an Amyloid-β₄₂ (Aβ₄₂) inducer.

Aftin-4	Amyloid-β	Neurological Disease
Aftin-4 is an *Amyloid-β₄₂* (Aβ₄₂) inducer.

HY-P4295

Z-Phe-Ala-diazomethylketone PADK	Cathepsin γ-secretase	Neurological Disease
Z-Phe-Ala-diazomethylketone binds directly to Aβ42 monomers and small oligomers. Z-Phe-Ala-diazomethylketone inhibits the formation of Aβ42 dodecamers and inhibits Aβ42 fibril formation in the solution. Z-Phe-Ala-diazomethylketone has the potential for neurodegenerative disorders research .

HY-144752

cSPM Cyclic spermine	Amyloid-β	Neurological Disease
cSPM (Cyclic spermine) is a Aβ42 inhibitor. cSPM could suppress the aggregation of three different peptides, Aβ42, amylin and insulin, and decreases cytotoxicity .

HY-111911

Xanthocillin X permethyl ether

Amyloid-β Neurological Disease

Xanthocillin X permethyl ether is a natural compound isolated from fungal extracts, with Aβ-42 lowering activity .

Xanthocillin X permethyl ether	Amyloid-β	Neurological Disease
Xanthocillin X permethyl ether is a natural compound isolated from fungal extracts, with Aβ-42 lowering activity .

HY-146140

Aβ-IN-4	Amyloid-β	Neurological Disease
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-146139

Aβ-IN-3	Amyloid-β	Neurological Disease
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Amyloid-β	Neurological Disease
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .

HY-103241

Ro 90-7501 1 Publications Verification	Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 is an *amyloid β₄₂* (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂**-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-108714

NGP555

γ-secretase Neurological Disease

NGP555 is a γ-secretase modulator. NGP555 Lowers the Amyloid Biomarker Aβ42 .
HY-112282

BI-1408

γ-secretase Neurological Disease

BI-1408 is a potent γ secretase modulator with an IC₅₀ of 0.04 μM for Aβ₄₂ .

NGP555	γ-secretase	Neurological Disease
NGP555 is a γ-secretase modulator. NGP555 Lowers the Amyloid Biomarker Aβ42 .

BI-1408	γ-secretase	Neurological Disease
BI-1408 is a potent γ secretase modulator with an IC₅₀ of 0.04 μM for Aβ₄₂ .

HY-P3793

Amyloid β-Protein (33-42) (TFA)	Amyloid-β	Neurological Disease
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity .

HY-153255

BACE1-IN-13	Beta-secretase	Neurological Disease
BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC₅₀ value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC₅₀ = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models .

HY-146151

γ-Secretase modulator 12	γ-secretase Amyloid-β	Neurological Disease
γ-Secretase modulator 12 (Compound 1a) is a γ-secretase modulator that can selectively decrease *amyloid-β42* (Aβ42) levels (IC₅₀** of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice .

HY-N0373

Licochalcone B 4 Publications Verification	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-117482

BPN-15606	γ-secretase	Neurological Disease
BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC₅₀ values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance .

HY-117482A

BPN-15606 besylate	γ-secretase	Neurological Disease
BPN-15606 besylate is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC₅₀ values of 7 nM and 17nM, respectively. BPN-15606 besylate lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 besylate has acceptable PK/PD properties, including bioavailability, half-life, and clearance .

HY-P3307

Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2	Tau Protein	Neurological Disease
Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is serum stable, non-toxic to neuronal cells, and selectivity inhibits the fibrilization of tau over Aβ₄₂.

HY-156179

DDC 2′,3′-O-disulfate	Amyloid-β	Neurological Disease
DDC 2′,3′-O-disulfate (compound 4) prevents the fibrillization and oligomerization of Aβ42. DDC 2′,3′-O-disulfate has the potential for Alzheimer's disease (AD) research .

HY-N0116

Hematoxylin 5 Publications Verification Natural Black 1; Haematoxylin	Amyloid-β	Others
Hematoxylin (Natural Black 1), a naturally occurring flavonoid compound derived from Caesalpinia sappan Linn.. Hematoxylin is a nuclear stain in histology and is also a potent Aβ42 fibrillogenesis inhibitor with an IC₅₀ of 1.6 μM.

HY-128581

γ-Secretase modulator 4	γ-secretase	Neurological Disease
γ-Secretase modulator 4 is a potent γ-secretase modulator, reduces the Aβ42 level with IC₅₀s of 0.014 μM and 0.017 μM in human and mouse, respectively .

HY-10016

E 2012 5+ Cited Publications	γ-secretase	Neurological Disease
E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .

HY-B0034

Donepezil Hydrochloride 5+ Cited Publications E2020	Cholinesterase (ChE)	Neurological Disease Cancer
Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-108499

NNC 26-9100	Somatostatin Receptor γ-secretase	Neurological Disease
NNC 26-9100 is a selective somatostatin sst4 receptor full agonist (K_i: 6 nM, EC₅₀: 2 nM). NNC 26-9100 decreases total soluble Aβ42, increases brain neprilysin activity and improves learning .

HY-153986

AEP-IN-2	Others	Neurological Disease
AEP-IN-2 is an asparagine endopeptidase (AEP) inhibitor via block AEP cleavage of APP and Tau. AEP-IN-2 has oral activity and decreases Aβ40 and Aβ42 and p-Tau levels .

HY-156180

DDC 3′-O-β-D glucuronide	Drug Metabolite	Neurological Disease
DDC 3′-O-β-D glucuronide (compound 5) is a drug metabolite that can prevent the fibrillization and oligomerization of Aβ42. DDC 3′-O-β-D glucuronide has potential for the research of Alzheimer's disease .

HY-146251

BuChE-IN-6	Cholinesterase (ChE) Amyloid-β	Neurological Disease
BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ₄₂ self-aggregation .

HY-P990078

Remternetug LY3372993	Amyloid-β	Neurological Disease
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ that aggregates into amyloid plaques .

HY-B1786A

(E/Z)-Sulindac sulfide	γ-secretase Amyloid-β	Neurological Disease
(E/Z)-Sulindac sulfide is a potent γ-secretase modulator (GSM). (E/Z)-Sulindac sulfide selectively reduces Aβ42 production in favor of shorter Aβ species. (E/Z)-Sulindac sulfide can be used for researching Alzheimer’s disease .

HY-150049

γ-Secretase modulator 13	Amyloid-β	Neurological Disease
γ-Secretase modulator 13 (compound 4) is a gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC₅₀ value of 163 nM. γ-Secretase modulator 13 can be used in the study of Alzheimer's disease .

HY-B0034S1

Donepezil-d4 hydrochloride E2020-d₄	Cholinesterase (ChE)	Neurological Disease
Donepezil-d₄ (hydrochloride) is the deuterium labeled Donepezil hydrochloride. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].

HY-B0034S

Donepezil-d5 hydrochloride E2020-d₅	Cholinesterase (ChE)	Neurological Disease
Donepezil-d₅ (hydrochloride) is deuterium labeled Donepezil (Hydrochloride). Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].

HY-N12321

2',3'-Dihydroxy-4',6'-dimethoxychalcone	Others	Metabolic Disease
2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Neurological Disease
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-150050

gamma-secretase modulator 5	Amyloid-β	Neurological Disease
gamma-secretase modulator 5 (compound 22d) is a brain-penetrant gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC₅₀ value of 60 nM. gamma-secretase modulator 5 can be used in the study of Alzheimer's disease .

HY-10009

Semagacestat 10+ Cited Publications LY450139	γ-secretase Amyloid-β Notch	Neurological Disease
Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC₅₀s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC₅₀ of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease .

HY-17406

Tolcapone 1 Publications Verification Ro 40-7592	COMT Amyloid-β Apoptosis	Neurological Disease Cancer
Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC₅₀ of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .

HY-17406S

Tolcapone-d7 Ro 40-7592 d₇	Isotope-Labeled Compounds COMT Amyloid-β	Neurological Disease
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

HY-120789

PF-06648671	γ-secretase	Neurological Disease
PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease .

HY-103442

CGP52411 DAPH	EGFR Amyloid-β	Neurological Disease Cancer
CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC₅₀ of 0.3 μM. CGP52411 blocks the toxic influx of Ca ²⁺ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .

HY-14533

K 01-162 K162	Amyloid-β	Neurological Disease
K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ₄₂ peptide with an EC₅₀ value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease .

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-14399

Itanapraced 1 Publications Verification CHF5074; CSP-1103	γ-secretase Apoptosis	Neurological Disease
Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC₅₀ values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .

HY-17406S1

Tolcapone-d4 Ro 40-7592-d₄	Isotope-Labeled Compounds COMT Amyloid-β Apoptosis	Neurological Disease Cancer
Tolcapone-d₄ is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].

Cat. No.	Product Name	Target	Research Area

HY-P4295

Z-Phe-Ala-diazomethylketone PADK	Cathepsin γ-secretase	Neurological Disease
Z-Phe-Ala-diazomethylketone binds directly to Aβ42 monomers and small oligomers. Z-Phe-Ala-diazomethylketone inhibits the formation of Aβ42 dodecamers and inhibits Aβ42 fibril formation in the solution. Z-Phe-Ala-diazomethylketone has the potential for neurodegenerative disorders research .

HY-P3793

Amyloid β-Protein (33-42) (TFA)	Amyloid-β	Neurological Disease
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity .

HY-P3307

Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2	Tau Protein	Neurological Disease
Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is serum stable, non-toxic to neuronal cells, and selectivity inhibits the fibrilization of tau over Aβ₄₂.

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P3781

(Met(O)35)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .

HY-P5905

Citrullinated amyloid-β (1-42) peptide (human) Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P1119

WRW4 3 Publications Verification	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide .

HY-P1119A

WRW4 TFA	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4 TFA, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 TFA specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-111911

Xanthocillin X permethyl ether	Structural Classification Microorganisms Antifungal Antibiotics Source classification Disease Research Other Antibiotics	Amyloid-β
Xanthocillin X permethyl ether is a natural compound isolated from fungal extracts, with Aβ-42 lowering activity .

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Structural Classification other families Source classification Plants Steroids	Amyloid-β
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .

HY-N0373

Licochalcone B 4 Publications Verification	Chalcones Flavonoids Leguminosae Source classification Plants Glycyrrhiza uralensis Fisch.	Amyloid-β Apoptosis NOD-like Receptor (NLR)
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-N0116

Hematoxylin 5 Publications Verification Natural Black 1; Haematoxylin	Structural Classification Classification of Application Fields Leguminosae Caesalpinia sappan L. Source classification Other Diseases Phenols Polyphenols Plants Disease Research Fields	Amyloid-β
Hematoxylin (Natural Black 1), a naturally occurring flavonoid compound derived from Caesalpinia sappan Linn.. Hematoxylin is a nuclear stain in histology and is also a potent Aβ42 fibrillogenesis inhibitor with an IC₅₀ of 1.6 μM.

HY-N12321

2',3'-Dihydroxy-4',6'-dimethoxychalcone	Structural Classification Monophenols Labiatae Source classification Phenols Plants Erigeron breviscapus (Vant.) Hand.-Mazz.	Others
2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .

HY-W010041

Scyllo-Inositol	Structural Classification Natural Products Source classification Endogenous metabolite	Amyloid-β Endogenous Metabolite
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

Cat. No.	Product Name	Chemical Structure

HY-B0034S1

Donepezil-d4 hydrochloride
Donepezil-d₄ (hydrochloride) is the deuterium labeled Donepezil hydrochloride. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].

HY-B0034S

Donepezil-d5 hydrochloride
Donepezil-d₅ (hydrochloride) is deuterium labeled Donepezil (Hydrochloride). Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].

HY-17406S

Tolcapone-d7
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

HY-17406S1

Tolcapone-d4

Tolcapone-d₄ is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].

HY-B1588S

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks